The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer

[1]  Mathias Uhlén,et al.  Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer , 2012, Journal of Ovarian Research.

[2]  F. Pontén,et al.  RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. , 2011, Translational oncology.

[3]  J. Gustafsson,et al.  The different roles of ER subtypes in cancer biology and therapy , 2011, Nature Reviews Cancer.

[4]  A. Roessner,et al.  G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer , 2011, Breast Cancer Research and Treatment.

[5]  B. Olde,et al.  G Protein-Coupled Estrogen Receptor 1/G Protein-Coupled Receptor 30 Localizes in the Plasma Membrane and Traffics Intracellularly on Cytokeratin Intermediate Filaments , 2011, Molecular Pharmacology.

[6]  S. Das,et al.  GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERα) phosphorylation signals. , 2011, Endocrinology.

[7]  B. Olde,et al.  The GPER1 Agonist G-1 Attenuates Endothelial Cell Proliferation by Inhibiting DNA Synthesis and Accumulating Cells in the S and G2 Phases of the Cell Cycle , 2011, Journal of Vascular Research.

[8]  A. Ehinger,et al.  G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. , 2010, Molecular human reproduction.

[9]  F. Pontén,et al.  Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer , 2010, Journal of Translational Medicine.

[10]  Karin Jirström,et al.  Open Access RESEARCH , 2010 .

[11]  S. Ho,et al.  Activation of GPR30 inhibits growth of prostate cancer cells via sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrest , 2010, Cell Death and Differentiation.

[12]  C. Qualls,et al.  GPR 30 Predicts Poor Survival for Ovarian Cancer , 2010 .

[13]  Mathias Uhlén,et al.  Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer , 2010, BMC Cancer.

[14]  B. Casslén,et al.  Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. , 2009, Gynecologic oncology.

[15]  M. Fernö,et al.  Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer , 2009, Modern Pathology.

[16]  N. Joste,et al.  GPR30 predicts poor survival for ovarian cancer. , 2009, Gynecologic oncology.

[17]  S. Bulun,et al.  Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. , 2009, Cancer research.

[18]  B. Casslén,et al.  Estradiol Attenuates EGF-Induced Rapid uPAR Mobilization and Cell Migration via the G-protein-Coupled Receptor 30 in Ovarian Cancer Cells , 2009, International Journal of Gynecologic Cancer.

[19]  P. Leung,et al.  Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. , 2008, Molecular endocrinology.

[20]  E. Prossnitz,et al.  The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. , 2008, Endocrinology.

[21]  H. Ngan,et al.  Estrogen Receptor Subtypes in Ovarian Cancer: A Clinical Correlation , 2008, Obstetrics and gynecology.

[22]  King-Jen Chang,et al.  The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. , 2007, Taiwanese journal of obstetrics & gynecology.

[23]  Meenakshi Singh,et al.  GPR30: a novel indicator of poor survival for endometrial carcinoma. , 2007, American journal of obstetrics and gynecology.

[24]  Tudor I. Oprea,et al.  G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. , 2007, Cancer research.

[25]  D. Giri,et al.  Distribution of GPR30, a Seven Membrane–Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression , 2006, Clinical Cancer Research.

[26]  Eric R. Prossnitz,et al.  A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling , 2005, Science.

[27]  J. Dong,et al.  Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. , 2005, Endocrinology.

[28]  D. Katsaros,et al.  Involvement of Estrogen Receptor β in Ovarian Carcinogenesis , 2004, Cancer Research.

[29]  D. Katsaros,et al.  Involvement of estrogen receptor beta in ovarian carcinogenesis. , 2004, Cancer research.

[30]  T. Bäckström,et al.  Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. , 2001, International journal of oncology.

[31]  N. Auersperg,et al.  Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. , 2001, Endocrinology.

[32]  S. Nicosia,et al.  Estrogen stimulation of ovarian surface epithelial cell proliferation , 2000, In Vitro Cellular & Developmental Biology - Animal.

[33]  K. Bland,et al.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. , 2000, Molecular endocrinology.

[34]  G. Scambia,et al.  Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. , 1995, British Journal of Cancer.

[35]  P. Fisher,et al.  Cell cycle arrest. , 1995, Science.

[36]  R. Bast,et al.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. , 1991, American journal of obstetrics and gynecology.